Skip to main
SION

SION Stock Forecast & Price Target

SION Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 71%
Buy 14%
Hold 0%
Sell 14%
Strong Sell 0%

Bulls say

Sionna Therapeutics Inc is positioned to significantly enhance the quality of life for cystic fibrosis patients by developing innovative therapies that target previously undruggable aspects of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The potential market opportunity is substantial, with projected revenues of $3.2 billion for the SION-451 proprietary combination and $900 million for the SION-719 add-on, contingent upon demonstrating measurable lung function improvements over standard of care. As median survival for CF patients continues to lag behind average life expectancy, Sionna's strategic focus on refining CF treatments aligns well with the urgent need for more effective therapies in this space.

Bears say

The analysis indicates a negative outlook on Sionna Therapeutics Inc's stock due to several key fundamental risks. These include the potential for unexpected safety events or weaker than anticipated efficacy of pipeline drugs, which could impede clinical trial progress and reduce the company’s probability of success. Additionally, challenges related to regulatory approval, competitor actions, and pricing pressures, alongside the financial burden of being a non-revenue-generating entity, may hinder the company’s ability to generate future revenues, thereby affecting valuation and stock price stability.

SION has been analyzed by 7 analysts, with a consensus rating of Buy. 71% of analysts recommend a Strong Buy, 14% recommend Buy, 0% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sionna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sionna Therapeutics Inc (SION) Forecast

Analysts have given SION a Buy based on their latest research and market trends.

According to 7 analysts, SION has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sionna Therapeutics Inc (SION)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.